Resverlogix is active in this space and I ask what impact (if any) the failure of the Phase 3 Solanezumab study and the Expedition 3 Study, along with other work Biogen is doing will have on us?
http://fortune.com/2016/11/23/eli-lilly-alzheimers-drug/